Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
- Conditions
- Immune Thrombocytopenia
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Sobi, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT05369208
- Locations
- 🇯🇵
Sobi Site 105, Toyohashi, Aichi, Japan
🇯🇵Sobi Site 110, Toon City, Ehime, Japan
🇯🇵Sobi Site 118, Iizuka-shi, Fukuoka, Japan
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Sobi, Inc.
- Registration Number
- NCT05046327
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Sobi, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04638829
- Locations
- 🇺🇸
Sobi Site 110, Tucson, Arizona, United States
🇺🇸Sobi Site 119, Whittier, California, United States
🇺🇸Sobi Site 123, Washington, District of Columbia, United States
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
- Conditions
- Immune Thrombocytopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Sobi, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT04516967
- Locations
- 🇺🇸
Site 112, Phoenix, Arizona, United States
🇺🇸Site 103, Long Beach, California, United States
🇺🇸Site 119, Orange, California, United States
Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure
- Conditions
- Thrombocytopenia
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Sobi, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03554759
- Locations
- 🇺🇸
Dova Site, Philadelphia, Pennsylvania, United States
🇺🇸Dova Study Site, Milwaukee, Wisconsin, United States
🇺🇸Dova Study SIte, Roanoke, Virginia, United States
- Prev
- 1
- 2
- Next